IMV Competitors

IMV (NASDAQ:IMV) and Xenon Pharmaceuticals (NASDAQ:XENE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Institutional & Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 8.4% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares IMV and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares IMV and Xenon Pharmaceuticals' top-line revenue, earnings per share and valuation.

IMV has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for IMV and Xenon Pharmaceuticals, as reported by MarketBeat.

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Xenon Pharmaceuticals has a consensus price target of $25.25, suggesting a potential upside of 36.12%. Given IMV's higher probable upside, analysts clearly believe IMV is more favorable than Xenon Pharmaceuticals.

Summary

Xenon Pharmaceuticals beats IMV on 8 of the 14 factors compared between the two stocks.

IMV (NASDAQ:IMV) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.

Profitability

This table compares IMV and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares IMV and Lexicon Pharmaceuticals' top-line revenue, earnings per share and valuation.

Lexicon Pharmaceuticals has higher revenue and earnings than IMV. IMV is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for IMV and Lexicon Pharmaceuticals, as reported by MarketBeat.com.

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Lexicon Pharmaceuticals has a consensus price target of $9.40, suggesting a potential upside of 93.42%. Given IMV's stronger consensus rating and higher probable upside, equities research analysts plainly believe IMV is more favorable than Lexicon Pharmaceuticals.

Summary

Lexicon Pharmaceuticals beats IMV on 10 of the 14 factors compared between the two stocks.

IMV (NASDAQ:IMV) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 88.6% of Karyopharm Therapeutics shares are owned by institutional investors. 13.3% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

Profitability

This table compares IMV and Karyopharm Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares IMV and Karyopharm Therapeutics' top-line revenue, earnings per share and valuation.

IMV has higher earnings, but lower revenue than Karyopharm Therapeutics. IMV is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for IMV and Karyopharm Therapeutics, as reported by MarketBeat.com.

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Karyopharm Therapeutics has a consensus price target of $29.8750, suggesting a potential upside of 216.81%. Given IMV's higher probable upside, equities research analysts plainly believe IMV is more favorable than Karyopharm Therapeutics.

Summary

Karyopharm Therapeutics beats IMV on 8 of the 14 factors compared between the two stocks.

IMV (NASDAQ:IMV) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 48.0% of ZIOPHARM Oncology shares are owned by institutional investors. 2.3% of ZIOPHARM Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500.

Profitability

This table compares IMV and ZIOPHARM Oncology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares IMV and ZIOPHARM Oncology's top-line revenue, earnings per share and valuation.

IMV has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for IMV and ZIOPHARM Oncology, as reported by MarketBeat.com.

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. ZIOPHARM Oncology has a consensus price target of $5.90, suggesting a potential upside of 86.71%. Given IMV's stronger consensus rating and higher probable upside, equities research analysts plainly believe IMV is more favorable than ZIOPHARM Oncology.

Summary

ZIOPHARM Oncology beats IMV on 9 of the 14 factors compared between the two stocks.

IMV (NASDAQ:IMV) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares IMV and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Earnings & Valuation

This table compares IMV and Calliditas Therapeutics AB (publ)'s top-line revenue, earnings per share and valuation.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than IMV. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for IMV and Calliditas Therapeutics AB (publ), as reported by MarketBeat.com.

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, suggesting a potential upside of 56.92%. Given IMV's higher probable upside, equities research analysts plainly believe IMV is more favorable than Calliditas Therapeutics AB (publ).

Summary

Calliditas Therapeutics AB (publ) beats IMV on 8 of the 12 factors compared between the two stocks.

IMV (NASDAQ:IMV) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for IMV and Intercept Pharmaceuticals, as reported by MarketBeat.com.

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Intercept Pharmaceuticals has a consensus price target of $50.6957, suggesting a potential upside of 144.08%. Given IMV's stronger consensus rating and higher probable upside, equities research analysts plainly believe IMV is more favorable than Intercept Pharmaceuticals.

Volatility & Risk

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 23.7% of Intercept Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares IMV and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares IMV and Intercept Pharmaceuticals' top-line revenue, earnings per share and valuation.

IMV has higher earnings, but lower revenue than Intercept Pharmaceuticals. IMV is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Intercept Pharmaceuticals beats IMV on 8 of the 14 factors compared between the two stocks.